What is Radiesse?

RADIESSE^® and RADIESSE^® (+) are FDA-approved dermal fillers that are used to treat signs of aging, and smoothing moderate to severe facial fine lines, wrinkles, and folds, such as nasolabial folds (the creases that extend from the corner of your nose to the corner of your mouth). RADIESSE^® injections stimulate your body’s natural collagen, filling facial wrinkles and folds. RADIESSE^® can be used for wrinkles near the mouth, but should not be used for lip augmentation. RADIESSE^® is also used to restore lost volume in the back of the hands. A numbing cream is used to prevent the treatment from being unnecessarily uncomfortable.

RADIESSE^® and RADIESSE^® (+) IMPORTANT SAFETY INFORMATION

Who should not use RADIESSE^® or RADIESSE^® (+)?

You should not use RADIESSE^® or RADIESSE^® (+) if you have an allergy to any component of the product if you have a history of severe allergies, if you have a bleeding disorder, or if you are pregnant or breastfeeding. You should not use RADIESSE^® (+) if you have an allergy to lidocaine or medicines like it.

What is the most important information I should know about RADIESSE^® and RADIESSE^® (+)?

One of the risks with using these products is unintentional injection into a blood vessel. The chances of this happening are very small, but if it does happen, the complications can be serious, and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. If you have changes in your vision, signs of a stroke (including sudden difficulty speaking, numbness or weakness in your face, arms, or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion), white appearance of the skin, or unusual pain during or shortly after treatment, you should notify your health care practitioner immediately.

As with all procedures that involve an injection through the skin, there is a risk of infection.

• Do not use RADIESSE^® or RADIESSE^® (+) if you have a skin infection until it has healed.
• It is not known if RADIESSE^® or RADIESSE^® (+) is safe or effective in the lips, or in the area around the eyes.
• The microspheres in RADIESSE^® and RADIESSE^® (+) can be seen in X-rays and CT Scans. It is very important that you tell your healthcare provider that you have had RADIESSE^® or RADIESSE^® (+) dermal filler.
• If you have a history of herpes, you may experience a herpes breakout after receiving RADIESSE^® or RADIESSE^® (+).
• Injection in the back of the hand may result in temporary difficulty in performing activities. RADIESSE^® may cause nodules, bumps, or lumps in the back of the hand and can last up to 1 year.
• You should minimize strenuous activity and avoid extensive sun or heat exposure for about 24 hours after treatment and until any swelling or redness has resolved.

What should I tell my doctor before using RADIESSE^® or RADIESSE^® (+)?

Tell your health care provider if you are taking blood thinners or medicines that can interfere with the clotting of blood, such as aspirin or warfarin. These medicines might make it more likely that you will experience bruising or bleeding at the injection site. Tell your health care provider if you have any diseases, injuries or disabilities of the hand, if you have a history forming large, raised scars or if you have had any other skin treatments such as skin peels. If you have a history of allergic reactions or you’re allergic to any of the ingredients in Radiesse, you should avoid this procedure.

What are the most common adverse events with RADIESSE^® or RADIESSE^® (+)?

The most common adverse events seen in clinical studies of RADIESSE^® used in the hands include bruising, redness, swelling, pain, itching, nodules or bumps/lumps, difficulty performing activities, loss of sensation and other local side effects. The most common adverse events seen in clinical studies of RADIESSE^® or RADIESSE^® (+) used in the face include bruising, redness, swelling, pain, itching and other local side effects.

These are not all of the possible side effects with RADIESSE^® or RADIESSE^® (+). Merz collects information about adverse events seen with RADIESSE^® and RADIESSE^® (+) outside of clinical studies. These events are included in the RADIESSE^® and RADIESSE^® (+) Patient Information Guide based on an assessment of seriousness and potential causal relationship to RADIESSE^® or RADIESSE^® (+). Please see the Patient Information Guide available at www.radiesse.com for list of these events. Tell your health care provider about any side effects that bother you or do not go away.

Important: For full safety information, please visit www.Radiesse.com or call MyMerz Solutions at 1-844-469-6379

To schedule a consultation with one of our board-certified dermatologists or find out more information on whether or not RADIESSE^® might be right for you, contact our dermal filler Omaha experts at Advanced Dermatology of the Midlands today.

RADIESSE^® and RADIESSE^® (+) are available by prescription only.

References:

1. Berlin AL, Hussain M, Goldberg DJ. Calcium hydroxylapatite filler for facial rejuvenation: a histologic and immunohistochemical analysis. Dermatol Surg. 2008;34(suppl 1):S64-S67.
2. Yutskovskaya Y, Kogan E, Leshunov E. A randomized, split-face, histomorphologic study comparing a volumetric calcium hydroxylapatite and a hyaluronic acid-based dermal filler. J Drugs Dermatol. 2014;13(9):1047-1052.
3. Moers-Carpi M, Vogt S, Santos BM, Planas J, Vallve SR, Howell DJ. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg. 2007;33(suppl 2):S144-S151.
4. Bass LS, Smith S, Busso M, McClaren M. Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results. Aesthet Surg J. 2010;30(2):235-238.
5. RADIESSE® [Instructions for Use]. Franksville, WI: Merz North America, Inc.; 2016.
6. RADIESSE [Instructions for Use for the dorsum of the hand]. Franksville, WI: Merz North America, Inc.; 2016.